HCPCS code J3300: Billing guide for triamcinolone acetonide preservative free

Key Takeaways

HCPCS code J3300 describes an injection of triamcinolone acetonide, preservative free, 1 mg per unit (brand name: Triesence), used primarily in ophthalmology.

Each billing unit equals 1 mg; a standard 4 mg intravitreal dose requires 4 units on the claim.

Always use J3300 (not J3301) when the preservative-free formulation was administered; mixing these codes is the top claim denial trigger.

Pabau’s claims management software streamlines HCPCS J-code billing workflows, tracks modifier usage, and reduces denial rates for ophthalmology and specialty practices.

HCPCS code J3300 describes an injection of triamcinolone acetonide, preservative free, 1 mg — the brand-name product Triesence. Medicare Part B pays for it under the Average Sales Price methodology when the injection, most often an intravitreal injection for ophthalmology, is medically necessary.

This guide covers unit calculation, the JW/JZ modifiers, supporting ICD-10 codes, and the errors that trigger most J3300 denials.

HCPCS code J3300: Definition and clinical overview

Most ophthalmology denial queues share a common culprit: a biller who grabbed J3301 when the chart clearly documented Triesence. One digit of difference; a full claim rejection. Claims management software that flags drug-code mismatches at submission prevents exactly this outcome.

HCPCS code J3300 is a Level II HCPCS code maintained by the Centers for Medicare and Medicaid Services (CMS). Level II codes cover drugs, supplies, and services that CPT (HCPCS Level I) doesn’t, which is why the preservative-free formulation gets its own dedicated code instead of a general injection code.

The code is active for 2026 and covered under Medicare Part B as a physician-administered drug. Its primary clinical home is ophthalmology, where it is used for intravitreal injection into the vitreous cavity of the eye. It also appears in rheumatology and other specialties when a preservative-free corticosteroid injection is clinically indicated.

Triamcinolone acetonide preservative free: Drug information

Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory properties. Practices managing ophthalmology billing should understand the drug’s clinical profile because the formulation determines which code is correct. For practices also managing skin clinic billing workflows, corticosteroid injection coding appears across multiple specialties.

The preservative-free version, brand-named Triesence and manufactured by Alcon, was approved by the FDA for ophthalmic use. Preservatives present in standard formulations can be toxic to intraocular tissues, so J3300 exists specifically to capture this distinct clinical product.

Triamcinolone acetonide administered via prescription and drug management workflows needs to be tracked from order through administration. Key clinical facts for billers:

• Drug class: Corticosteroid (glucocorticoid)
• FDA-approved indications (ophthalmic): Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical therapy
• Primary route of administration: Intravitreal injection (into the vitreous cavity)
• Available concentration: Triesence is supplied as 40 mg/mL suspension (preservative free)
• Typical intravitreal dose: 4 mg (0.1 mL) per injection episode; this equals 4 units of J3300 on the claim
• Single-use vial: Supplied in single-use vials; drug wastage modifiers apply if the full vial is not used

Billing HCPCS code J3300: Units, dosage, and claim submission

Unit calculation errors are the second most common denial cause for J3300 claims. The rule is straightforward: 1 billing unit equals 1 mg of triamcinolone acetonide. If the physician administered 4 mg, bill 4 units. If 40 mg was administered (unusual for ophthalmic use but documented in some cases), bill 40 units.

Billing also differs by place of service. The claim amount and cost-sharing change depending on whether the service occurred in a physician office or a facility setting. See Bupa CCSD codes for comparable facility-vs-non-facility distinctions in other code sets.

When billing J3300 as a physician office claim, the drug cost is included in the non-facility reimbursement rate. In a hospital outpatient setting, only the administration code (typically CPT 67028 for intravitreal injection) appears on the physician claim. Billers frequently submit the drug code on hospital claims in error, which triggers a duplicate billing denial.

Medicare fee schedule and reimbursement for J3300

Medicare reimburses J3300 under the Average Sales Price (ASP) methodology. CMS calculates ASP quarterly based on manufacturer-reported sales data, then adds a 6% add-on payment as authorized under the Social Security Act. The same ASP-based methodology prices other specialty drug codes, such as HCPCS code Q5114.

Because ASP changes quarterly, any rate cited in a billing guide (including this one) should be verified against the CMS fee schedule lookup before submitting claims for a given quarter.

A practical guide to current fee schedule amounts alongside comparable procedure code fee schedules can help billing teams contextualize reimbursement levels across payer types.

• ASP file update schedule: CMS releases the ASP quarterly pricing file each January, April, July, and October
• OPPS setting: Hospital outpatient claims for J3300 are paid under the OPPS Ambulatory Payment Classification (APC) system, which may package the drug cost into a composite APC rate
• Beneficiary cost-sharing: Under Medicare Part B, the patient is responsible for 20% coinsurance after the Part B deductible is met
• 340B program impact: Hospitals participating in the 340B drug pricing program are subject to a reduced ASP-minus-22.5% payment for separately payable drugs including J3300

Applicable modifiers for J3300

Two modifiers are central to J3300 billing since CMS updated its drug-wastage policy in the 2023 Physician Fee Schedule Final Rule. Failing to apply the correct modifier is a compliance risk, not just a billing error. The same single-dose-vial logic governs other J-code drugs, including HCPCS code J1459.

CMS phased in the JW/JZ requirement for single-dose container drugs like J3300, a policy that also touches infusion and IV therapy practices billing single-dose vials. JZ became available for optional use on January 1, 2023, then mandatory on applicable single-dose-container claims from July 1, 2023.

Since October 1, 2023, Medicare claims for J3300 submitted without either modifier are returned as unprocessable rather than paid. Document the wastage decision in the administration note at the point of care, before the claim is generated.

ICD-10 diagnosis codes that support J3300 claims

Medical necessity for J3300 is established by the diagnosis codes linked to the claim. Medicare administrative contractors (MACs) use Local Coverage Determinations (LCDs) to define which ICD-10-CM codes support coverage for corticosteroid injections in their jurisdiction.

Always verify the applicable LCD for your MAC before relying on this reference list. Related retinal diagnosis coding is covered under ICD-10 code H35.9.

A diagnosis code alone does not guarantee coverage. Payers also evaluate whether the clinical record supports medical necessity, including documentation that less invasive treatments were considered or tried first.

J3300 vs J3301: Key differences

Coders regularly confuse these two codes. The difference is formulation-specific, not dose-specific. HCPCS code J3301 is the “not otherwise specified” code for triamcinolone acetonide that is not preservative free. Kenalog and generic equivalents fall under this code. Billing J3301 when Triesence was actually administered is a coding error, regardless of dose or indication.

NDC to HCPCS crosswalk for J3300

National Drug Codes (NDCs) are required on Medicaid claims for J3300. They are also required under the 340B program and for some commercial payer claims. Medicare Part B claims do not uniformly require NDC reporting on professional claims, but facility (UB-04) claims often do. The distinction matters: conflating Medicare and Medicaid NDC rules is a common billing configuration error.

The CMS NDC to HCPCS crosswalk maps NDC codes for Triesence to J3300. You can verify current NDC-to-HCPCS mappings using the AAPC HCPCS lookup or the PGM Billing HCPCS lookup, both of which include NDC data for J-codes.

Injectable drug codes for related specialties follow comparable NDC-to-code crosswalk logic, as with IVF CPT codes.

When reporting an NDC on a claim line:

• Use the 11-digit NDC format (5-4-2) with qualifier “N4” on electronic claims
• Report the NDC of the actual package dispensed, not the manufacturer’s bulk NDC
• Report the NDC quantity in the applicable unit of measure (UN for vials, ML for liquid volume)
• Verify the NDC has not been discontinued; Alcon periodically updates Triesence packaging NDCs

Streamline your J-code billing with Pabau

Pabau's claims management software tracks HCPCS J-code claims, flags modifier errors before submission, and supports the documentation workflows ophthalmology and specialty practices need to reduce denials.

Book a demo

Documentation requirements for J3300 claims

Insufficient documentation is the third most cited reason for J3300 post-payment audit findings. The chart must contain enough detail for a reviewer to independently confirm that the drug administered matches the billed code, the dose was medically necessary, and all modifier decisions are supported.

Practices that invest in digital intake forms prompt providers to capture required fields at the point of care, which cuts down on missing documentation.

Standardizing documentation for J3300 claims also addresses healthcare documentation compliance requirements that apply to all injectable drug records. The required documentation elements include:

• Diagnosis: ICD-10-CM code and supporting clinical rationale; must link directly to the injection indication
• Drug name and formulation: Must specify “triamcinolone acetonide, preservative free” or “Triesence” (not just “triamcinolone”)
• Dose administered: Specific milligram amount (e.g., “4 mg administered via intravitreal injection, right eye”)
• Route of administration: Intravitreal injection, including which eye (right, left, or bilateral)
• Medical necessity statement: Brief note on why the drug was selected and why conservative measures were inadequate
• Wastage documentation (if JW modifier used): Amount drawn, amount administered, and amount discarded from the vial
• Zero-waste attestation (if JZ modifier used): Statement that the full dose drawn was administered with no remainder discarded
• Lot number and expiration date: Required for single-use vials under most state pharmacy regulations and recommended for all J-code administrations

Common billing errors and how to avoid them

Denial patterns for J3300 are predictable: the same six recurring errors account for most rejections. Revisiting medical billing basics reinforces the same core principle: code what was documented, document what was done.

• Using J3301 instead of J3300: Occurs when the biller defaults to the more familiar NOS code without checking the chart for formulation. Fix: build a charge capture rule that flags any triamcinolone charge without the specific formulation confirmed in the encounter note.
• Incorrect unit calculation: J3300 is billed per 1 mg; a 4 mg dose requires 4 units. Billers accustomed to J3301 (10 mg per unit) sometimes carry that ratio incorrectly. Fix: include the unit-per-mg conversion in the charge entry screen or charge master.
• Missing JW or JZ modifier: Since October 1, 2023, claims for single-use vial J-codes submitted without one of these modifiers can be returned as unprocessable. Fix: configure your billing system to require modifier selection before J3300 can be submitted.
• Absent NDC on Medicaid claims: Medicaid requires the 11-digit NDC on all drug claims; submitting without it generates an automatic rejection. Fix: link the NDC to the drug item in your charge master so it populates automatically.
• Missing diagnosis linkage: A J3300 line item without a diagnosis pointer to a supporting ICD-10 code will deny for lack of medical necessity. Fix: use a diagnosis crosswalk that requires a covered ICD-10 code before the J3300 charge clears the pre-submission queue.
• Billing drug in facility setting: When Triesence is administered in a hospital outpatient or ASC setting, the physician should bill the administration CPT code only; the drug is bundled into the facility claim. Fix: configure place-of-service rules in your billing workflow.

Prior authorization and payer policies for HCPCS code J3300

Medicare Part B generally does not require prior authorization (PA) for J3300, provided the claim is supported by a covered ICD-10 diagnosis and medical necessity documentation. However, verify the policy with your MAC, as some contractors issue Local Coverage Determinations that include pre-authorization language for specific indications.

Commercial payer policies differ substantially from Medicare. Many plans require PA for Triesence because less expensive alternatives (J3301 formulations) exist. Step therapy requirements are common: a payer may require documented failure of a non-preservative-free triamcinolone injection before approving Triesence.

Billing teams at ophthalmology practices should maintain a payer-specific PA matrix updated at least annually. PA-management patterns for other intravitreal drug codes, like HCPCS code J7312, follow a similar review cycle.

Key payer policy checkpoints:

• Medicare Part B: Generally no PA required; LCD-defined coverage criteria apply
• Medicaid: PA requirements vary by state; many states require PA for brand-name drugs when a generic is available
• Commercial plans: PA commonly required; step therapy (trial of J3301 first) is frequent
• 340B-covered entities: No additional PA required, but NDC reporting and 340B exclusion modifiers must be handled correctly
• Appeal process: For PA denials, submit the operative note, clinical rationale for the preservative-free formulation, and any prior treatment failure documentation

The billing workflows for medical procedure billing codes across different specialty contexts share the same PA documentation principles: document the clinical rationale before the service, not after the denial.

Conclusion

J3300 claims fail for predictable reasons: wrong code (J3301 instead of J3300), wrong units, missing modifier, missing NDC, or absent diagnosis linkage. Every one of those errors is preventable with the right charge-capture rules and documentation workflow in place.

Pabau’s claims management software supports HCPCS J-code billing with pre-submission modifier validation, charge master drug-code configuration, and documentation prompts that capture the fields auditors look for. To see how Pabau handles J-code billing for ophthalmology and specialty practices, book a demo.

Continue your research

Need to code a same-visit eye exam alongside the injection? CPT code 92002 covers the intermediate eye exam ophthalmology practices often bill on injection visit days.

Coding a retinal finding that doesn’t fit the standard diagnosis list? ICD-10 code H35.89 covers other specified retinal disorders that can support related claims.

Billing an unspecified globe disorder on an ophthalmology claim? ICD-10 code H44.9 covers unspecified disorders of the globe.

Frequently asked questions